Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069277 · ClinicalTrials.gov registry record · Phase 1
Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00069277 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 21 participants.
The verdict
NCT00069277, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The malignancies (advanced solid tumors) that have been chosen for evaluation of E7389 are those where E7389 has demonstrated significant pre-clinical anti-tumor activity, both in vitro and in vivo. The ultimate goal is to demonstrate the clinical activity of E7389 in the treatment of these, and potentially other, tumor types.
Interventions
- DRUG E7389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2003-08 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069277
The ClinicalTrials.gov registry entry for NCT00069277 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7389 is the first listed.
NCT00069277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00069277 about?
NCT00069277 is a clinical study titled "Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors". The malignancies (advanced solid tumors) that have been chosen for evaluation of E7389 are those where E7389 has demonstrated significant pre-clinical anti-tumor activity, both in vitro and in vivo. The ultimate goal is to demonstrate the clinical activity of E7389 in the treatment of these, and pot...
What is the current status of trial NCT00069277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2003-08. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00069277?
The interventions under investigation include: E7389 (DRUG).
Who is sponsoring clinical trial NCT00069277?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.